Causal Effects of Gut Microbiome on Autoimmune Liver Disease: a Two-sample Mendelian Randomization Study

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2023 Oct 3

PMID 37789337

Authors

Yugang Fu

Jiacheng Li

Yingying Zhu

Chong Chen

Jing Liu

Simin Gu

Yiyuan Zheng

Yong Li

Affiliations

Soon will be listed here.

Abstract

Background: Epidemiological studies have indicated a potential link between the gut microbiome and autoimmune liver disease (AILD) such as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The relationship between the gut microbiome and autoimmune liver disease is still uncertain due to confounding variables. In our study, we aim to shed light on this relationship by employing a two-sample Mendelian randomization approach.

Methods: We conducted a two-sample Mendelian randomization (MR) study using the R package "TwoSampleMR". The exposure data consisted of genetic variants associated with 194 bacterial traits obtained from the MiBioGen consortium. Summary statistics for AILD were obtained from the GWAS Catalog website. Furthermore, a series of sensitivity analyses were performed to validate the initial MR results.

Results: There were two, four and three bacteria traits associated with an increased risk of AIH. PBC, and PSC respectively. In contrast, there were five, two and five bacteria traits associated with a decreased risk for AIH, PBC and PSC. Notably, the genus_Clostridium_innocuum_group showed a negative association with AIH (OR = 0.67, 95% CI: 0.49-0.93), and the genus_Actinomyces was found to be genetically associated with a decreased risk of PSC (OR = 0.62, 95% CI: 0.42-0.90).

Conclusions: Our study identified the causal impact of specific bacterial features on the risk of AILD subtypes. Particularly, the genus_Clostridium_innocuum_group and the genus_Actinomyces demonstrated significant protective effects against AIH and PSC respectively. These findings provide further support for the potential use of targeted probiotics in the management of AILD.

Citing Articles

Analysis of the fecal microbiome and metabolome in dairy cows with different body condition scores.

Saraphol B, Hinthong W, Chienwichai P, Pumipuntu N, Reamtong O, Srisook T PLoS One. 2025; 20(3):e0319461.

PMID: 40063888 PMC: 11893135. DOI: 10.1371/journal.pone.0319461.

Genetically predicted plasma metabolites mediate the causal relationship between gut microbiota and osteosarcoma.

Qin X, Fan Z, Qiao S, Li J, Lv J Sci Rep. 2025; 15(1):7277.

PMID: 40025200 PMC: 11873036. DOI: 10.1038/s41598-025-91869-1.

Genetically predicted immune cells mediate the association between gut microbiota and autoimmune liver diseases.

Zhang J, Hu Y, Xu J, Shao H, Zhu Q, Si H Front Microbiol. 2024; 15:1442506.

PMID: 39736991 PMC: 11684339. DOI: 10.3389/fmicb.2024.1442506.

Causal impact of gut microbiota on five liver diseases: insights from mendelian randomization and single-cell RNA sequencing.

Li N, Chen X, Xiong S, Cheng Y, Deng J, Zhang J Front Genet. 2024; 15:1362139.

PMID: 39588518 PMC: 11586359. DOI: 10.3389/fgene.2024.1362139.

The causal relationship between gut microbiota and 2 neoplasms, malignant and benign neoplasms of bone and articular cartilage: A two-sample Mendelian randomization study.

Lv J, Qin X, Wang J, Li J, Bai J, Lan Y Medicine (Baltimore). 2024; 103(46):e40519.

PMID: 39560555 PMC: 11576038. DOI: 10.1097/MD.0000000000040519.

References

Davies N, Holmes M, Davey Smith G . Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018; 362:k601. PMC: 6041728. DOI: 10.1136/bmj.k601. View

Ji S, Juran B, Mucha S, Folseraas T, Jostins L, Melum E . Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet. 2016; 49(2):269-273. PMC: 5540332. DOI: 10.1038/ng.3745. View

Brion M, Shakhbazov K, Visscher P . Calculating statistical power in Mendelian randomization studies. Int J Epidemiol. 2013; 42(5):1497-501. PMC: 3807619. DOI: 10.1093/ije/dyt179. View

Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T . Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019; 4(3):492-503. DOI: 10.1038/s41564-018-0333-1. View

Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S . A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021; 53(10):1415-1424. DOI: 10.1038/s41588-021-00931-x. View

Rao B, Lou J, Lu H, Liang H, Li J, Zhou H . Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis. Front Cell Infect Microbiol. 2021; 11:656674. PMC: 8170700. DOI: 10.3389/fcimb.2021.656674. View

Tang R, Wei Y, Li Y, Chen W, Chen H, Wang Q . Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2017; 67(3):534-541. DOI: 10.1136/gutjnl-2016-313332. View

Trivedi P, Hirschfield G . Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut. 2021; 70(10):1989-2003. DOI: 10.1136/gutjnl-2020-322362. View

Liu Q, Tian H, Kang Y, Tian Y, Li L, Kang X . Probiotics alleviate autoimmune hepatitis in mice through modulation of gut microbiota and intestinal permeability. J Nutr Biochem. 2021; 98:108863. DOI: 10.1016/j.jnutbio.2021.108863. View

10.

Boef A, Dekkers O, le Cessie S . Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015; 44(2):496-511. DOI: 10.1093/ije/dyv071. View

11.

Kummen M, Thingholm L, Ruhlemann M, Holm K, Hansen S, Moitinho-Silva L . Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology. 2021; 160(5):1784-1798.e0. PMC: 7611822. DOI: 10.1053/j.gastro.2020.12.058. View

12.

Boehm F, Zhou X . Statistical methods for Mendelian randomization in genome-wide association studies: A review. Comput Struct Biotechnol J. 2022; 20:2338-2351. PMC: 9123217. DOI: 10.1016/j.csbj.2022.05.015. View

13.

Quraishi M, Acharjee A, Beggs A, Horniblow R, Tselepis C, Gkoutos G . A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. J Crohns Colitis. 2020; 14(7):935-947. PMC: 7392170. DOI: 10.1093/ecco-jcc/jjaa021. View

14.

Ma L, Zhang L, Zhuang Y, Ding Y, Chen J . Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells. Cell Commun Signal. 2022; 20(1):83. PMC: 9166466. DOI: 10.1186/s12964-021-00819-7. View

15.

Kurilshikov A, Medina-Gomez C, Bacigalupe R, Radjabzadeh D, Wang J, Demirkan A . Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat Genet. 2021; 53(2):156-165. PMC: 8515199. DOI: 10.1038/s41588-020-00763-1. View

16.

Ruhlemann M, Heinsen F, Zenouzi R, Lieb W, Franke A, Schramm C . Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis. Gut. 2016; 66(4):753-754. DOI: 10.1136/gutjnl-2016-312180. View

17.

Burgess S, Thompson S . Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017; 32(5):377-389. PMC: 5506233. DOI: 10.1007/s10654-017-0255-x. View

18.

Carbone M, Neuberger J . Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2013; 60(1):210-23. DOI: 10.1016/j.jhep.2013.09.020. View

19.

Chapman M, Thorburn D, Hirschfield G, Webster G, Rushbrook S, Alexander G . British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019; 68(8):1356-1378. PMC: 6691863. DOI: 10.1136/gutjnl-2018-317993. View

20.

Hemani G, Zheng J, Elsworth B, Wade K, Haberland V, Baird D . The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018; 7. PMC: 5976434. DOI: 10.7554/eLife.34408. View